These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 17977229)

  • 1. [Asymmetric dimethylarginine: metabolism, arginine paradox, pathophysiology].
    Gilinskiĭ MA
    Usp Fiziol Nauk; 2007; 38(3):21-39. PubMed ID: 17977229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
    Yamagishi S; Ueda S; Okuda S
    Med Hypotheses; 2007; 69(4):922-4. PubMed ID: 17368960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function.
    Richir MC; Bouwman RH; Teerlink T; Siroen MP; de Vries TP; van Leeuwen PA
    JPEN J Parenter Enteral Nutr; 2008; 32(6):613-21. PubMed ID: 18974239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The L-arginine paradox: Importance of the L-arginine/asymmetrical dimethylarginine ratio.
    Bode-Böger SM; Scalera F; Ignarro LJ
    Pharmacol Ther; 2007 Jun; 114(3):295-306. PubMed ID: 17482266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asymmetric dimethylarginine (ADMA): the silent transition from an 'uraemic toxin' to a global cardiovascular risk molecule.
    Fliser D
    Eur J Clin Invest; 2005 Feb; 35(2):71-9. PubMed ID: 15667575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asymmetric dimethylarginine: a new player in the pathogenesis of renal disease?
    Zoccali C; Kielstein JT
    Curr Opin Nephrol Hypertens; 2006 May; 15(3):314-20. PubMed ID: 16609301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical significance of asymmetric dimethylarginine.
    Siroen MP; Teerlink T; Nijveldt RJ; Prins HA; Richir MC; van Leeuwen PA
    Annu Rev Nutr; 2006; 26():203-28. PubMed ID: 16848705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effects of endogenous L-arginine analogues on nitric oxide synthesis in platelets: role in platelet hyperaggregability in hypertension.
    de Meirelles LR; Mendes-Ribeiro AC; Santoro MM; Mendes MA; da Silva MN; Mann GE; Brunini TM
    Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1267-71. PubMed ID: 17973865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor.
    Böger RH
    J Nutr; 2004 Oct; 134(10 Suppl):2842S-2847S; discussion 2853S. PubMed ID: 15465797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asymmetric dimethylarginine, NO and collateral growth.
    Kocaman SA
    Anadolu Kardiyol Derg; 2009 Oct; 9(5):417-20. PubMed ID: 19819795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low plasma concentrations of arginine and asymmetric dimethylarginine in premature infants with necrotizing enterocolitis.
    Richir MC; Siroen MP; van Elburg RM; Fetter WP; Quik F; Nijveldt RJ; Heij HA; Smit BJ; Teerlink T; van Leeuwen PA
    Br J Nutr; 2007 May; 97(5):906-11. PubMed ID: 17381965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of asymmetric dimethylarginine and endothelial dysfunction.
    Böger RH
    Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dimethylarginine dimethylaminohydrolase (DDAH)--a critical regulator of hypertensive left ventricular hypertrophy?
    Bai Y; Hui R
    Med Hypotheses; 2008; 70(5):962-6. PubMed ID: 17983707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L-Arginine therapy in cardiovascular pathologies: beneficial or dangerous?
    Böger RH
    Curr Opin Clin Nutr Metab Care; 2008 Jan; 11(1):55-61. PubMed ID: 18090660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of asymmetric dimethylarginine (ADMA) on heart failure development.
    Liu X; Hou L; Xu D; Chen A; Yang L; Zhuang Y; Xu Y; Fassett JT; Chen Y
    Nitric Oxide; 2016 Apr; 54():73-81. PubMed ID: 26923818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases.
    Böger RH; Bode-Böger SM
    Semin Thromb Hemost; 2000; 26(5):539-45. PubMed ID: 11129410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease.
    Ueda S; Yamagishi S; Kaida Y; Okuda S
    Nephrology (Carlton); 2007 Dec; 12(6):582-90. PubMed ID: 17995585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asymmetric Dimethylarginine (ADMA) in cardiovascular and renal disease.
    Alpoim PN; Sousa LP; Mota AP; Rios DR; Dusse LM
    Clin Chim Acta; 2015 Feb; 440():36-9. PubMed ID: 25444745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule.
    De Gennaro Colonna V; Bianchi M; Pascale V; Ferrario P; Morelli F; Pascale W; Tomasoni L; Turiel M
    Med Sci Monit; 2009 Apr; 15(4):RA91-101. PubMed ID: 19333216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effects of kaempferol against endothelial damage by an improvement in nitric oxide production and a decrease in asymmetric dimethylarginine level.
    Xiao HB; Jun-Fang ; Lu XY; Chen XJ; Chao-Tan ; Sun ZL
    Eur J Pharmacol; 2009 Aug; 616(1-3):213-22. PubMed ID: 19549512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.